In November 2004, a national target was set for hospitals in England to reduce the methicillin-resistant Staphylococcus aureus (MRSA) bactermia rate by 60 percent by April 2008 against the number during 2003/04 (baseline year). Sarma, et al. (2013) report that in their organization the number of MRSA bactermias has risen since 2002 and peaked at 75 in 2005/06. A target was set to reduce the number and string of specific and non-specific interventions was introduced including universal MRSA screening. This study analyzes the impact of universal MRSA screening using a quasi-experimental design using routinely gathered data.
Â
This study used data gathered routinely for clinical governance, quality control, financial management and outbreak monitoring purposes. Interrupted Time Series (ITS) analysis of 15 pre- and 19 post- universal MRSA screening (and decolonization) quarterly numbers of bactermias was carried out where methicillin-sensitive Staphylococcus aureus (MSSA) numbers served as non-equivalent dependent variable (control).
Â
An immediate sharp decrease in MRSA bactermias was observed following the universal MRSA screening (and decolonization) commenced in Q2, 2007. The number dropped sharply from 23 (Q2, 2007) to 10 (Q3, 2007) all MRSA bactermias, and, from 15 (Q2, 2007) to 6 (Q3, 2007) for bactermias >= 48 hours of hospitalization. The declining trend continued reaching zero in Q2, 2009 and Q4, 2010 for those with >=48 hours of hospitalization and, all bactermias, respectively. ITS analysis revealed significant impact of universal MRSA screening on all MRSA bactermias (beta2 -0.554, p 0.000) and those with >=48 of hospitalization (beta2 -0.577, p 0.001), respectively. Impact estimation predicted 17 and 13 bactermias for all and those with >=48 hours hospitalization, respectively in the 19th quarter post-intervention, if the intervention did not occur. The number of MRSA isolates from non-blood culture systemic sources as percentage of admissions also dropped significantly from 3.32 percent in Q2, 2007 to 1.51 percent in Q3, 2007 (beta2 -0.506, p 0.000) which is still running low at 0.33 percent at the end of Q1, 2012. On the other hand, there was no statistically significant impact of universal screening on MSSA bactermias.
Â
The researchers conclude that of all interventions, the universal MRSA screening (and decolonization) is the most effective intervention associated with significant and sharp drop in MRSA burden. Their research was published in Antimicrobial Resistance and Infection Control.Â
Reference: Sarma JB, Marshall B, Cleeve V, Tate D and Oswald T. Impact of universal screening on MRSA bactermias in a single acute NHS organisation (2006--12): interrupted time-series analysis Antimicrobial Resistance and Infection Control 2013, 2:2 doi:10.1186/2047-2994-2-2
Â
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.